Correlation between EGFR mutation status and the efficacy of first-line chemotherapy in advanced lung adenocarcinoma

Jun LI,Tong-peng XU,Ren-hua GUO,Yan-hong GU,Yong-mei YIN,Kai-hua LU,Yong-qian SHU,Shi-dai JIN
DOI: https://doi.org/10.14053/j.cnki.ppcr.201708006
2017-01-01
Abstract:Objective To investigate the relationship between EGFR mutations and the response to first-line chemotherapy in patients with advanced lung adenocarcinoma.Methods A total of 103 patients with stage Ⅲ b/Ⅳ lung adenocarcinoma who received pemetrexed plus platinum (cisplatin or carboplatin) regimen as first-line chemotherapy were investigated retrospectively,and their clinical data was assessed according to EGFR mutation.Results In 103 patients,36 cases (35.0%) harbored EGFR-activating mutations and 67 patients (65.0%) were EGFR wild-type.All patients received first-line pemetrexed plus platinum (cisplatin or carboplatin) regimen therapies.The objective response rate (ORR) was 27.2% and disease control rate (DCR) was 71.8%.Patients with EGFR-activating mutations had a higher DCR than EGFR wild-type patients (86.1% vs.64.2%,P =0.018).The median progression free survival (PFS) of all enrolled patients was 6 months,and PFS in patients with EGFR-activating mutations was significantly higher than that in EGFR wild-type patients (8 months vs.5 months,P =0.004).Cox multivariate analysis indicated the EGFR-activating mutation was an independent factor affecting PFS (HR =0.684,95% CI:0.541 ~ 0.865,P =0.002).Conclusion Advanced lung adenocarcinoma patients with EGFR mutation respond better to first-line chemotherapy than EGFR wild-type patients.EGFR mutation is a predictor for PFS of first-line chemotherapy in advanced lung adenocarcinoma patients.
What problem does this paper attempt to address?